Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

Efficace, F., Mahon, F. X., Richter, J., Piciocchi, A., Cipriani, M., Nicolini, F. E., Mayer, J., Zackova, D., Janssen, J. J. W. M., Panayiotidis, P., Vestergaard, H., Koskenvesa, P., Almeida, A., Hjorth-Hansen, H., Martinez-Lopez, J., Olsson-Strömberg, U., Hochhaus, A., Berger, M. G., Etienne, G. & Klamova, H. & 4 andra, Faber, E., Rousselot, P., Pfirrmann, M. & Saussele, S., aug. 2024, I: Leukemia. 38, 8, s. 1722-1730 9 s.

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial

Flygt, H., Söderlund, S., Richter, J., Saussele, S., Koskenvesa, P., Stenke, L., Mustjoki, S., Dimitrijevic, A., Stentoft, J., Majeed, W., Roy, L., Wolf, D., Dreimane, A., Gjertsen, B. T., Gedde-Dahl, T., Ahlstrand, E., Markevärn, B., Hjorth-Hansen, H., Janssen, J. & Olsson-Strömberg, U., 2024, I: Leukemia. 38, s. 781–787 7 s.

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Real-world experience of novel multiple myeloma treatments in a large, single-center cohort in Finland

Loponen, H., Mehtälä, J., Ylisaukko-Oja, T., Bruck, O., Porkka, K., Koskenvesa, P. M., Saukkonen, K. & Lievonen, J., 6 okt. 2023, I: eJHaem. 4, 4, s. 1019-1029 11 s.

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia

Hohtari, H., Pallisgaard, N., Kankainen, M., Ellonen, P., Brück, O., Siitonen, T., Säily, M., Sinisalo, M., Pyörälä, M., Itälä-Remes, M., Koskenvesa, P., Elonen, E., Mustjoki, S. & Porkka, K., aug. 2022, I: Haematologica. 107, 8, s. 1971-1976 6 s.

Forskningsoutput: Tidskriftsbidrag › Brev › Vetenskaplig

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation

Awad, S. A., Brück, O., Shanmuganathan, N., Järvinen, T., Lähteenmäki, H., Klievink, J., Ibrahim, H., Kytölä, S., Koskenvesa, P., Hughes, T. P., Branford, S., Kankainen, M. & Mustjoki, S., 20 apr. 2022, I: Blood cancer journal. 12, 4, 4 s., 69.

Forskningsoutput: Tidskriftsbidrag › Brev › Vetenskaplig